101. Zoledronic acid versus pamidronate: cost minimisation in bone metastasis
- Author
-
Francisco J Bautista, Xavier Badia, Eduardo Echarri, Luis Lizán, José-Miguel Rodríguez-Sasiaín, John Slof, Ramon Pla, Alfonso Dg Hurlé, M Antonia Mangues, and Miguel A Wood
- Subjects
Oncology ,medicine.medical_specialty ,Hypercalcaemia ,business.industry ,Health Policy ,medicine.medical_treatment ,Bone metastasis ,medicine.disease ,Malignancy ,Surgery ,Clinical trial ,Radiation therapy ,Zoledronic acid ,Breast cancer ,Internal medicine ,medicine ,business ,Multiple myeloma ,medicine.drug - Abstract
SummaryThe objective of this study was to evaluate the economic and organisational consequences of the substitution of pamidronate with zoledronic acid in the adjunct treatment of bone metastasis in patients with breast cancer and multiple myeloma in a European context.A cost minimisation analysis was carried out. Clinical data were extracted from clinical trials of pamidronate versus zoledronic acid. Resource consumption and cost data were collected at different Spanish oncology infusion sites.While the acquisition cost of zoledronic acid is higher compared with pamidronate, zoledronic acid is superior to pamidronate for the treatment of hypercalcaemia of malignancy and in avoiding palliativeradiotherapy. Moreover, it is at least as effective as 90 mg pamidronate in reducing skeletal complications in patients with bone lesions from myeloma or breast cancer. It therefore reduced nurse monitoring, occupation of infusion chairs and radiotherapy sessions, implying savings in health care resources. The net of...
- Published
- 2005